This is a phase I study using the murine monoclonal antibody 14G2a in the treatment of patients with GD2 antigen positive malignant melanoma and small cell carcinoma of the lungs. Designed to evaluate the tolerance & toxicity of escalating doses of the antibody and to determine the maximum tolerated dose in humans, patients are treated in escalating doses of three.
Showing the most recent 10 out of 570 publications